Usual care + structured support
Test explanation, preferred support, and permitted movement practice.
A temporary nerve implant is an intriguing starting point. The bigger opportunity is helping people recover safe movement, confidence, and daily life after surgery.
My perspective on the project, ready for a written exchange.
Subject: Re: Temporary nerve stimulation and orthopedic recovery
Hi Aman,
Thank you for reaching out. I’d be glad to share my perspective. I’m a physical therapist and massage therapist, a Northwestern Feinberg DPT graduate (2006), and the owner of Movement Solutions in Wilmette. I’ve worked in rehabilitation since 1997 and opened Movement Solutions in 2009. My work includes persistent pain, orthopedic and postsurgical recovery, movement coordination, and helping people become more aware of how they move. I draw on manual therapy, movement retraining, graded strengthening, and clinical neurodynamics.
One idea I’d bring to your project is that pain can speak to us for many reasons. Tissue healing and nerve irritation matter, and so can previous experiences, expectations, sleep, stress, and how supported or in control someone feels. Some of these influences operate outside conscious awareness. Pain deserves attention, but its intensity does not give us a direct measurement of tissue damage or tell us the cause by itself.
I’m interested in what this device could make possible: getting out of a chair, walking to the bathroom, sleeping, or participating in appropriate rehabilitation. I also wonder about the meaning the device takes on. It might become associated with relief and confidence; for some people, its sensations or presence could become associated with uncertainty or pain. Actual irritation or a device complication would also need to be investigated. I would want the research to distinguish these possibilities rather than assume one explanation.
I see an important place for technology that supports life and function—stents and shunts are familiar examples when appropriately indicated. Alongside that, my broader interest is helping people understand their bodies, move with more confidence, and connect with other people. Attachment and interpersonal neurobiology offer questions about trust, choice, and support, although they do not yet tell us who will benefit from this implant.
Please send me a list of your team’s questions, along with the specific paper or device description, the surgery you are considering, and its current stage of development. I can work through them thoughtfully by email at my own pace. I’ve gathered the research and possible study questions at https://pain-to-movement.labnolabs.com/ as a starting point.
Best,
Lance Labno, PT, DPT, LMT
Movement Solutions
Background checked against the Movement Solutions biography. [31] The research behind the questions is explained below.
Pain often draws attention and prompts protection. It is not a reliable meter of damage, and it does not always carry a decipherable message. Biological, psychological, and social processes can contribute together. [12]
Follow a connection; then ask what could be observed.
Conceptual synthesis. Lines mean “consider together,” not measured causal strength. This map does not diagnose a person’s pain.
Rotate to see the layers. Flatten to read them together.
A conceptual 3D model, not brain anatomy, a biological hierarchy, or measured distances. The layers coexist: physical mechanisms, learned meaning, and relationship context. Color and depth imply no evidence ranking.
Read across each row before carrying a finding into this proposed implant study. Colors mark evidence type; words show its reach. This is a scoped evidence map, not a formal GRADE certainty assessment.
| Claim or approach | Mechanism / effect studied | Clinical recovery relevance | Aman’s exact implant |
|---|---|---|---|
| Electrical / thermal Rogers prototypes | Animal tests [1–3] | Not established here | Exact device unconfirmed |
| Clinical percutaneous PNS | Human randomized trials [6–7] | Some pain/function benefit | Different hardware |
| Learned cues & expectations | Human experiments [24–28] | Clinical wording result [27] | Implant transfer untested |
| Attachment & support | Mixed human findings [9–11,14] | No reliable responder rule | Untested moderator |
| Right-brain regulation / IPNB | Conceptual synthesis [13,30] | No implant outcome trial | Untested framework |
These are four study conditions, not four kinds of patients. The axes indicate whether an investigational device and an added support/practice program are included. All groups retain appropriate usual care.
Test explanation, preferred support, and permitted movement practice.
Test the novel relationship: does support help translate analgesia into participation?
Establish the recovery course with ethical, credible control procedures.
Estimate device benefit with the same basic communication and rehabilitation access.
Proposed 2×2 factorial design, contingent on device safety, approvals, feasibility, and a power calculation. A sham may be appropriate only if ethically acceptable. Interaction tests require more power than a small feasibility pilot.
A device has physical effects and an experience attached to it. Its appearance, sensations, or treatment setting might come to predict relief, uncertainty, or pain. That is a plausible research question—not an established problem with Rogers’s implant.
Surgical healing, inflammation, nerve effects, stimulation delivery, or a device complication can contribute to pain.
Investigate symptoms and device function clinically.Prior experiences, instructions, attention, and expectations can change pain and willingness to move—even with the same experimental stimulus. [24] [25]
Measure meaning and expectations alongside physical findings.| Primary experiment | What happened | What it does not establish |
|---|---|---|
| Jensen 2012 40 healthy volunteers [24] | After visible cues were paired with high/low heat, masked cues changed pain ratings at test. | Supports nonconscious triggering of learned responses. Does not show unconscious initial learning, hidden trauma, or an implant effect. |
| Bingel 2011 Experimental heat pain [25] | With fixed opioid concentration, positive and negative expectations changed observed analgesia. | Does not mean expectations cancel drug pharmacology or explain every treatment failure. |
| Karacaoglu 2023 Sham TENS [26] | Conditioning/instructions produced nocebo effects with differences across visits and groups. | External sham device, not an implant. Fibromyalgia did not produce the hypothesized stronger nocebo response. |
| Varelmann 2010 140 obstetric patients [27] | Gentler versus harsher anticipatory wording: median immediate injection pain 3 versus 5 out of 10. | A short procedure, not long-term recovery. Supports accurate, measured language; never withholding risk information. |
| Thomaidou 2020 140 enrolled; 122 included [28] | Laboratory counterconditioning reduced learned nocebo pain more than extinction. | Clinical transfer remains unproven. This is not a reason to deliberately induce fear or pain after surgery. |
| Meulders 2011 Movement–pain learning [29] | Movement paired with pain acquired threat value in an experimental setting. | Does not make all guarding learned, unnecessary, or safe to override. |
These are proposed research steps requiring clinical investigators, ethics review where applicable, and an appropriate analysis plan. A small pilot can establish feasibility; it cannot validate a responder algorithm.
Dan Siegel’s interpersonal neurobiology (IPNB) brings embodied experience, mental processes, and relationships into one interdisciplinary framework. “Integration” refers to linking differentiated elements. It is a way to organize questions—not a proven implant treatment. [30]
Can the person describe what they feel and distinguish location, intensity, timing, and the task involved?
Observe: symptom descriptions and task-specific responses.Does the person understand the plan and have meaningful control over permitted options?
Observe: understanding, perceived agency, and preferences.Does support feel responsive and welcome? Who, if anyone, does the person want involved?
Observe: trust, preferred support, and participation.These are proposed operational questions inspired by IPNB. Neither IPNB nor right-brain attachment theory establishes which neural process is causing an individual’s pain. Attachment involves distributed systems; “right brain” is not a readiness score. [13] [23]
| Example | Physical role | Question for whole-person care |
|---|---|---|
| Coronary stent [32] | Helps hold a narrowed artery open when clinically indicated. | What ongoing care, understanding, and activity support does the person need? |
| CSF shunt [33] | Diverts cerebrospinal fluid for selected hydrocephalus cases. | Can the person recognize problems and follow the monitoring plan? |
| Proposed temporary nerve implant | Intended nerve modulation or block; exact mechanism still needs confirmation. | Does relief translate into safe activity, and what experience does the person have while using it? |
These examples illustrate different purposes, not equivalent evidence or indications. Body awareness and social support do not replace a clinically necessary device.
Aman’s email describes an entrepreneurship team exploring a possible use for technology—not a confirmed clinical trial.
Aman identifies himself as a Northwestern industrial engineering senior, Class of 2027, with a computer science minor and Kellogg certificate. His team wants clinician interviews about early orthopedic recovery and a temporary nerve stimulation implant associated with Professor John Rogers.
The exact device, course instructor, teammates, protocol, sponsor, and clinical development stage are not supplied.
“Can the device create a useful window for safe movement—and what else does a person need to use that window?”
This is a proposed clinical framing for Lance to review. It is not a quote from Aman or a claim that the implant already improves rehabilitation.
| Potential value | Missing piece to test | Movement Solutions contribution |
|---|---|---|
| Localized, adjustable analgesia | Does benefit occur during walking, transfers, or exercise—not only at rest? | Choose repeatable, surgery-appropriate tasks. |
| Less reliance on rescue medication | Comparable pain control, side effects, sleep, and actual medication use | Connect analgesia timing with therapy participation. |
| A temporary interface | Working lifetime, breakdown products, retained components, and failure/removal plan | Test whether the whole setup is practical at home. |
| More opportunity to practice movement | Strength, sensation, balance, surgical restrictions, and delayed symptom response | Document both what a person can do and the support needed. |
| A stronger recovery experience | Whether explanation, choice, and preferred support add benefit | Help design a reproducible communication approach. |
These are proposed benefits and design questions. Existing clinical PNS trials support investigating analgesia; they do not validate every Rogers prototype. [6] [7]
The closest wording match is the 2022 electronic pain-block cuff. That is a research lead, not identification of Aman’s device. Ask for the paper, patent, or technical brief.
Lee and colleagues developed a bioresorbable cuff delivering kilohertz-frequency alternating current to block conduction in rat peripheral nerves. Reported fast, reversible block; experimental power/control used external connections.
Must establish: human benefit, onset responses, selective sensory effects, and safe motor function. This is not interchangeable with low-frequency clinical PNS. [1]
Reeder and colleagues used a soft, bioresorbable microfluidic interface to cool a nerve and reversibly reduce conduction. It requires fluid delivery; it is not an electrical stimulation implant.
Must establish: temperature safety, selective effects, home hardware burden, and human recovery outcomes. [2]
Park and colleagues report a largely bioresorbable cuff with a heater and temperature sensor. Rat sciatic conduction was suppressed and recovered on cooling; wireless power was demonstrated. First online December 2025.
Must establish: human thermal safety and what remains after degradation. Gold elements are biocompatible, not bioresorbable. [3]
2025 wireless dual stimulator: Ahn and colleagues studied peripheral nerve regeneration in animal models. Regeneration is a different endpoint from early postoperative analgesia. [4]
2026 programmable polyphasic system: Kim and colleagues developed wireless power and light-controlled waveforms. The reported platform includes cardiac and diaphragm applications; its existence does not establish pain relief after orthopedic surgery. [5]
Only Aman and John Rogers are named in the email. Publication authors below are relevant to the technology; their involvement in Aman’s course team has not been confirmed.
| Person / connection | Verified relevance | Useful question |
|---|---|---|
| Aman Mahendra Student contact | Education and project purpose are self-described in the email. The linked professional profile lists Northwestern education, 2023–2027. [17] | Which course, instructor, teammates, and specific device are involved? |
| John A. Rogers Northwestern professor | Director of the Querrey Simpson Institute for Bioelectronics; expertise in soft, bio-integrated and transient electronics. Coauthor of the candidate devices. [18] | Which mechanism and development milestone are relevant now? |
| Matthew R. MacEwan WashU collaborator | Research spans peripheral nerve interfaces, regeneration, and transient electronics. Coauthor on electronic and thermal pain-block work. [1] [3] [19] | How are nerve health, motor effects, and repeat-use safety evaluated? |
| Geumbee Lee / Emily Ray 2022 publication authors | Lead authors on the electronic pain-block paper; Lee is also a corresponding author of the thermal interface paper. [1] [3] | What does the prototype actually block, for how long, and with what external equipment? |
| Jeonghwan Park / Hak-Young Ahn Recent device authors | Park leads the thermal-interface paper; Ahn leads the wireless dual-stimulator paper and coauthors the thermal work. [3] [4] | Which performance measures transfer to a postsurgical use case? |
| Colin K. Franz Shirley Ryan AbilityLab | Physician-scientist and Electrodiagnostic Laboratory director studying neural injury, repair, and transient bioelectronic implants. Corresponding author on the 2025 regeneration study. [4] [21] | Could a rehabilitation collaborator help distinguish nerve recovery, analgesia, and functional performance? |
| Brian Ilfeld / Johnathan Goree Independent clinical comparators | Lead authors of clinical PNS trials discussed below. Not established as members of Aman’s or Rogers’s project. [6] [7] | What can an acute or persistent-pain trial teach about controls and endpoints? |
No faculty member is assumed to teach Aman’s entrepreneurship course. Credentials support expertise, not the effectiveness of a particular device.
Fourteen days of percutaneous PNS or sham followed ambulatory orthopedic surgery. In the first week, median opioid use was 5 versus 48 mg oral morphine equivalents; mean daily average pain was 1.1 versus 3.1 out of 10. Both groups also received a single-injection nerve block. [6]
Bars use a 0–10 pain scale. Group means, not an individual prediction. Pilot size, mixed surgeries, and a different device limit transfer to Rogers’s prototypes.
During weeks 5–8, at least 50% pain reduction occurred in 12/20 PNS participants (60%) versus 5/21 sham participants (24%). Six-minute walking distance also improved more with PNS at end of treatment. This studied persistent pain after knee replacement—not the first postoperative week. [7]
Small study; devices remained for eight weeks. DoD and SPR Therapeutics supported the study. Review disclosures and the full protocol before choosing it as a model.
TENS during knee-replacement rehabilitation reduced some movement pain compared with standard care, but did not significantly outperform placebo TENS. Anxiety and catastrophizing were associated with some response differences. TENS is a surface treatment, not the proposed implant. [8]
Do not turn these exploratory associations into implant eligibility rules. Measure expectations and assess whether participants can guess their allocation.
Krahé et al. found higher attachment avoidance was associated with greater laser-pain ratings when a partner was present rather than absent. This was a particular laboratory context, not surgical recovery. [9]
Jaltare et al. found a smaller area of experimentally induced secondary hyperalgesia during partner handholding. Attachment did not moderate that support effect. Different support, setting, and outcome can yield different findings. [10]
Pfeifer et al. compared unexplained musculoskeletal pain rehabilitation with hip-replacement care for osteoarthritis. Greater avoidance related to less pain improvement in the former and greater improvement in the latter. Different populations and treatments prevent a causal interpretation. [11]
Pain is a real sensory and emotional experience shaped by biological, psychological, and social influences. Nociceptive activity alone does not tell us everything about a person’s pain. [12]
Allan Schore’s regulation theory emphasizes early attachment, nonverbal communication, emotional regulation, and right-hemisphere contributions. It offers a conceptual reason to attend to voice, timing, facial expression, and interpersonal comfort. [13]
Boundary: this is a theoretical synthesis, not evidence that a right-brain intervention improves implant outcomes. Attachment and pain cannot be reduced to a single hemisphere. A small social-emotion imaging study found task-dependent associations in both right- and left-sided regions. [23] No reviewed study establishes a “right-brain readiness” test for this device.
Ask whether the person wants a preview, quiet practice, verbal coaching, a support person, or more control over pauses. Explain what sensations to expect and what should prompt stopping.
Record perceived safety, confidence for a specific task, participation, and adverse responses. Do not infer attachment from eye contact, muscle guarding, pain intensity, HRV, or a clinician’s impression.
This is a proposed care-and-study approach. It does not measure hemispheric activity or prove a neural mechanism.
| Possible tendency | Question worth asking | Support to offer and test |
|---|---|---|
| Worry that help will disappear | “What would make the plan feel more predictable?” | Consistent explanations, a clear check-in plan, and a stop signal. |
| Preference for self-reliance or distance | “Would you prefer to try independently, with me nearby?” | Choice, privacy, and optional coaching; do not force closeness. |
| Mixed or changing preferences | “What is helpful right now?” | Recheck preferences across tasks and days. |
These are conversation prompts, not diagnostic categories. With consent, the ECR-RS questionnaire could measure attachment anxiety and avoidance as separate dimensions. Specify whether the target is close relationships generally or one particular relationship. It is an exploratory research measure, not an implant-response screen. [22] In using it, select its version, permissions, and scoring with a qualified behavioral researcher. People with insecure attachment may still improve substantially.
A 72-person chronic-pain rehabilitation study reported comparable treatment effectiveness across attachment groups. [14] A sequential-block clinician-training study found mixed results and did not establish a clear main pain benefit over usual care. It was not a randomized implant trial. [15]
A post-cesarean attachment pilot is indexed, but the accessible PubMed record has no abstract. Its results are not used here; obtain the complete paper before drawing conclusions. [16]
No reviewed evidence demonstrates that attachment-informed communication changes the electrical effect of this implant, identifies a validated responder subgroup, or prevents persistent postsurgical pain.
Proposed research sequence—not an approved protocol. Start with the smallest study that resolves the current uncertainty.
Interview patients, therapists, surgeons, and anesthesia staff about one procedure and the first two weeks. Ask for concrete episodes: getting to the bathroom, rising from a chair, or sleeping.
Output: a task map, current treatment pathway, and practical barriers. Interviews test need and feasibility, not efficacy. Use consent and de-identified examples.
Review exact-device bench and animal data, functional lifetime, tissue response, motor/sensory effects, degradation, and recovery after shutoff.
Gate: qualified investigators determine readiness, regulatory requirements, and ethics approval before any investigational implantation. Do not translate animal settings into clinical doses.
Once authorized, choose one surgery and standardized usual care. Test placement, home operation, retention, follow-up, safety, and whether the chosen task can be measured reliably.
Output: recruitment and missing-data estimates, adverse events, and outcome variability to plan a powered trial. A small pilot cannot reliably identify responder subgroups.
Compare active device + usual care with credible sham + the same usual care, if an invasive sham is ethically justified. Keep rescue analgesia available. Use concealed allocation and blinded outcome assessment.
Alternative: an active-comparator trial when sham is unsuitable, acknowledging expectancy and masking limitations.
Prospective recovery cohort: follow one surgical population using the measurement schedule below. This can identify recovery predictors and practical barriers, but cannot tell whether a characteristic predicts extra benefit from the device.
Support feasibility experiment: with appropriate research review and consent, compare a structured, patient-chosen preview-and-coaching approach with an equally attentive standard explanation. Maintain usual analgesia and therapy in both groups. Measure acceptability, task completion, pain, and confidence; partner involvement or touch is optional. This can test the support component while device development continues.
A later, adequately powered 2 × 2 factorial trial could separate device effects from an added structured support intervention. Everyone receives respectful care, rehabilitation, and rescue treatment.
| Usual supportive communication | Added structured support | |
|---|---|---|
| Active device | Device benefit under usual care | Device + added choice, preview, and check-ins |
| Control device | Reference condition | Added support without active stimulation |
Match contact time where possible. Define the support script and fidelity checks; do not train staff to diagnose attachment by behavior. Predefine the interaction analysis. A benefit from support would not, by itself, prove Schore’s proposed mechanism.
| When | Measure | Why |
|---|---|---|
| Before surgery | Baseline pain and function; medications; sleep; expectations; anxiety; optional attachment dimensions and support preferences | Describe participants and prespecify a few plausible modifiers. |
| Early recovery / days 1–14 | Pain during the same safe task; distance or time; assistance needed; strength/sensation; rescue medication; adverse events | Separate analgesia from useful, safe activity. |
| Weeks 2 and 6 | Patient-specific function; treatment burden; participation; medication use; device/tissue review | Look beyond a single immediate pain score. |
| Months 3 and 6 | Persistent pain, function, nerve symptoms, further treatment | Assess durability and delayed harms; do not assume prevention. |
Illustrative measurement choices. Timing, loading, and permitted movement must match the operation and surgeon’s restrictions. No patient data is collected.
Predicting recovery is different from predicting treatment benefit. A person might improve with either treatment. A useful responder model must estimate whether the device adds benefit compared with control.
Aman can send his team’s questions in writing. These five questions help identify what would make the project useful and testable.
Please send the paper or technical description, intended surgery, mechanism, external equipment, and development stage.
Recommendation: Start with one clearly defined surgery and prototype; distinguish entrepreneurship discovery from a clinical protocol.
Choose a meaningful task and describe the expected improvement in pain, assistance, capacity, or participation.
Recommendation: Pair a pain measure with one safe, repeatable functional task and adverse-event monitoring.
How will you capture expectations and the experience of using it while investigating physical causes of symptoms?
Recommendation: Include a small expectations-and-experience component; avoid labeling people as nocebo-prone.
Could explanation, choice, permitted movement practice, or patient-preferred human support improve the recovery experience?
Recommendation: Pilot a reproducible support component, then consider the four-condition design shown above.
Which baseline measures and treatment interactions would you prespecify, and how would you validate any responder claim?
Recommendation: Use continuous measures, adequate sample size, uncertainty intervals, and independent validation. Attachment is exploratory, not an eligibility rule.
This is a targeted research synthesis, not a systematic review. Searches covered primary device papers, university profiles, human pain trials, attachment experiments, and clinical cohorts. Strongest direct evidence and conflicting findings are included. Sources were reviewed through accessible full text or abstracts; access limitations are marked.
Primary animal/device study; Rogers-group full-text copy available.
Primary animal/device study. Cooling mechanism.
Primary animal/device study; full text reviewed. Most, not all, components bioresorbable.
Primary animal study; regeneration endpoint.
Primary platform study; not a human orthopedic analgesia trial.
66 patients; 14-day PNS; early postoperative outcomes.
Persistent pain population; small randomized trial; financial support disclosed in publisher record.
317 participants; randomized, blinded, placebo-controlled trial.
39 women; laboratory pain and partner presence; limited generalizability.
37 women; partner handholding experiment; abstract reviewed.
Observational cohorts; musculoskeletal pain rehabilitation and hip replacement.
Authoritative terminology; distinguishes pain from nociception.
Author’s theoretical review. Does not test orthopedic implants.
72-person cohort; attachment did not determine rehabilitation effectiveness.
Sequential-block design, not randomized; mixed findings and exploratory mediation.
Indexed letter; no abstract in accessible record. Results not used.
Public education listing; project details come from supplied email. Do not confuse activity by other people with Aman’s biography.
Official faculty profile and research expertise.
Official research listing for MacEwan; publication affiliation is used for the specific studies.
Official publication list; used to check newer related platforms.
Official clinical and research profile.
Measure developer guidance; separate anxiety/avoidance dimensions and relationship targets.
Small healthy-adult study; task-dependent, distributed regional findings, not a surgical treatment study.
Two laboratory experiments, 40 healthy volunteers; visible acquisition followed by visible or masked cue testing.
Fixed-concentration remifentanil and experimental heat pain; not an implant trial.
69 at baseline, 56 at follow-up. Mixed group/time findings; no evidence of greater nocebo effects in fibromyalgia.
Randomized wording experiment, 140 obstetric patients; immediate injection pain.
140 enrolled; 122 included. Laboratory conditioning and attenuation; clinical transfer unproven.
Human experimental movement–pain conditioning; not a postoperative treatment trial.
Originator’s explanation of an interdisciplinary framework; not independent confirmation of clinical efficacy.
Official practice biography: massage training 1997, Northwestern DPT 2006, practice founded 2009.
Purpose and indications of stents; authoritative patient information.
Clinical overview including cerebrospinal-fluid diversion with a shunt.